Medicare bill heads to White House
Executive Summary
President Bush's plan to veto legislation, H.R. 6331, intended to stave off cuts in Medicare physician rates is motivated primarily by provisions to make up for those cuts with reductions in payments to Medicare Advantage plans, White House officials indicated during a July 10 press briefing. Still intact in H.R. 6331 are a number of provisions in the drug area, including Medicare payment incentives for physicians to use electronic prescribing; bundled payments for dialysis-related services, including drugs; Medicare coverage of benzodiazepines; permanence of Medicare Part D coverage of all or substantially all drugs in six classes, and suspension of Medicaid average manufacturer price rules. The Senate passed the measure July 9 by what, if it holds, is a veto-proof 69-30 margin. It is identical to the version that passed the House 355-59 on June 24 (1"The Pink Sheet," June 30, 2008, p. 23)
You may also be interested in...
Medicare Bill Strikes Out Again In Senate After Home Run In House
Momentum from a surprising House passage of a slightly modified version of the Sen. Max Baucus-penned Medicare physician payment legislation was not quite enough to carry the bill on a second try in the Senate on June 26
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.